PLAUR and Hepatic fibrosis: In preclinical models, chimeric antigen receptor-modified macrophages (CAR-Ms) targeting the urokinase plasminogen activator receptor (uPAR) have shown significant efficacy in reducing liver fibrosis (Dai et al., 2024).